Can a Hormone-Blocking drug boost chemo against cervical cancer?

NCT ID NCT07763496

Not yet recruiting Disease control Sponsor: ARCAGY/ GINECO GROUP Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding relacorilant—a drug that blocks a stress-related hormone—to the chemotherapy nab-paclitaxel can shrink tumors in people with recurrent or metastatic cervical cancer. Participants have already tried platinum-based chemo and immunotherapy without lasting benefit. The study will measure how many people respond, how long responses last, and how safe the combination is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: relacorilant combined with nab-paclitaxel
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced cervical cancer whose disease has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase study, so the treatment may not work as hoped or may cause side effects. Results need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Recurrence Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OR METASTATIC CERVICAL CANCER

Contacts and locations

Locations

Centre Léon Bérard

Lyon, France
Groupe Hospitalier Diaconesses Croix Saint-Simon

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.